A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin

British Journal of Cancer

Volumn 91, Issue 10, 2004, Pages 1800-1807

  Glynn, S A ^a   Gammell, P ^a   Heenan, M ^a   O'Connor, R ^a   Liang, Y ^a   Keenan, J ^a   Clynes, M ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Adhesion, Rho GTPases; Doxorubicin (adriamycin); Drug resistance; Invasion; Motility; Paclitaxel (taxol)

Indexed keywords

CARBOPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; PACLITAXEL; SCLEROPROTEIN; VINCRISTINE;

ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER INVASION; CELL ADHESION; CELL MOTILITY; CELL SURFACE; CLONAL VARIATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IC 50; MEMBRANE BINDING; PATIENT SELECTION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL ADHESION; CELL MOVEMENT; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM INVASIVENESS; PACLITAXEL; PHENOTYPE; SELECTION (GENETICS);

EID: 10844229333     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602221     Document Type: Article

References (35)

1. Akashi H, Han HJ, Iizaka M, Nakamura Y (2000) Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac. Int J Cancer 88: 873-880
2. Albini A, Melchiori A, Santi L, Liotta LA, Brown PD, Stetler-Stevenson WG (1991) Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 83: 775-779
3. Bjornland K, Lehne G, Johansen HT, Fodstad O, Rugstad HE, Aasen AO, Ree AH (1998) Human hepatoma cells rich in P-glycoprotein display enhanced in vitro invasive properties compared to P-glycoprotein-poor hepatoma cells. Oncol Res 10: 255-262
4. Brambilla G (1994) Verapamil: what is the mechanism of its anticarcinogenic activity? Br J Cancer 69: 792
5. Cailleau R, Olive M, Cruciger QV (1978) Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In vitro 14: 911-915
6. Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572
7. Duffy CP, Elliott CJ, O'Connor RA, Heenan MM, Coyle S, Cleary IM, Kavanagh K, Verhaegen S, O'Loughlin CM, NicAmhlaoibh R, Clynes M (1998) Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer 34: 1250-1259
8. Etievant C, Pauwels O, Kiss R (1993) Digital cell image analysis of verapamil-induced effects in chemosensitive and chemoresistant neoplastic cell lines. J Cancer Res Clin Oncol 120: 76-84
9. Giavazzi R, Miller L, Hart IR (1983) Metastatic behavior of an adriamycin-resistant murine tumor. Cancer Res 43: 5081-5086
10. Haimeur A, Conseil G, Deeley RG, Cole SP (2004) The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5: 21-53
11. Hikawa T, Mori T, Abe T, Hori S (2000) The ability in adhesion and invasion of drug-resistant human glioma cells. J Exp Clin Cancer Res 19: 357-362
12. Kotchetkov R, Cinatl J, Blaheta R, Vogel JU, Karaskova J, Squire J, Hernaiz-Driever P, Klingebiel T, Cinatl Jr J (2003) Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model. Int J Cancer 104: 36-43
13. Liang Y, McDonnell S, Clynes M (2002) Examining the relationship between cancerinvasion/metastasis and drug resistance. Curr Cancer Drug Targets 2: 257-277
14. Liang Y, Meleady P, Cleary I, McDonnell S, Connolly L, Clynes M (2001) Selection with melphalan or paclitaxel (Taxol) yields variants with different patterns of multidrug resistance, integrin expression and in vitro invasiveness. Eur J Cancer 37: 1041-1052
15. Liu H, Lei X, Han R (1998) Anti-invasion activity of several plant-originated anticancer drugs with different mechanism of action. Yao Xue Xue Bao 33: 18-21
16. Lucke-Huhle C (1994) Permissivity for methotrexate-induced DHFR gene amplification correlates with the metastatic potential of rat adenocarcinoma cells. Carcinogenesis 15: 695-700
17. Martin A, Clynes M (1991) Acid phosphatase endpoint for in vitro toxicity tests. In vitro Cell Dev Biol 27A: 183-184
18. Martin A, Clynes M (1993) Comparison of five microplate colorimetric assays for in vitro cytotoxicity testing and cell proliferation assays. Cytotechnology 11: 49-58
19. Moran E, Redmond A, Clynes M (1992) Preliminary studies of a monoclonal antibody raised to the over expressed plasma membrane associated glycoprotein of a multidrug resistant cell line. Biochem Soc Trans 20: 58S
20. Naumov GN, MacDonald IC, Chambers AF, Groom AC (2001) Solitary cancer cells as a possible source of tumour dormancy? Semin Cancer Biol 11: 271-276
21. Repesh LA, Drake SR, Warner MC, Downing SW, Jyring R, Seftor EA, Hendrix MJ, McCarthy JB (1993) Adriamycin-induced inhibition of melanoma cell invasion is correlated with decreases in tumor cell motility and increases in focal contact formation. Clin Exp Metast 11: 91-102
22. Sahai E, Olson MF, Marshall CJ (2001) Cross-talk between Ras and Rho signalling pathways in transformation favours proliferation and increased motility. EMBO J 20: 755-766
23. Scaddan PB, Dufresne MJ (1993) Characterization of cysteine proteases and their endogenous inhibitors in MCF-7 and adriamycin-resistant MCF-7 human breast cancer cells. Invasion Metast 13: 301-313
24. Sgadari C, Toschi E, Palladino C, Barillari G, Carlei D, Cereseto A, Ciccolella C, Yarchoan R, Monini P, Sturzl M, Ensoli B (2000) Mechanism of paclitaxel activity in Kaposi's sarcoma. J Immunol 165: 509-517
25. Silbergeld DL, Chicoine MR, Madsen CL (1995) In vitro assessment of Taxol for human glioblastoma: chemosensitivity and cellular locomotion. Anticancer Drugs 6: 270-276
26. Stearns ME, Wang M (1992) Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases. Cancer Res 52: 3776-3781
27. Sun J, He ZG, Cheng G, Wang SJ, Hao XH, Zou MJ (2004) Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit 10: 5-14
28. Terzis AJ, Thorsen F, Heese O, Visted T, Bjerkvig R, Dahl O, Arnold H, Gundersen G (1997) Proliferation, migration and invasion of human glioma cells exposed to paclitaxel (Taxol) in vitro. Br J Cancer 75: 1744-1752
29. Torimura T, Ueno T, Kin M, Ogata R, Inuzuka S, Sugawara H, Kurotatsu R, Shimada M, Yano H, Kojiro M, Tanikawa K, Sata M (1999) Integrin alpha6beta1 plays a significant role in the attachment of hepatoma cells to laminin. J Hepatol 31: 734-740
30. Tovey SM, Witton CJ, Bartlett JM, Stanton PD, Reeves JR, Cooke TG (2004) Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res 6: 246-251
31. Ueda S, Ogata S, Tsuda H, Kawarabayashi N, Kimura M, Sugiura Y, Tamai S, Matsubara O, Hatsuse K, Mochizuki H (2004) The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 29: e1-e8
32. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR, Klusens LF, Grogan TM, Saclarides TJ, Roninson IB (1991) Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51: 2720-2726
33. Welch DR, Lobl TJ, Seftor EA, Wack PJ, Aeed PA, Yohem KH, Seftor RE, Hendrix MJ (1989) Use of the membrane invasion culture system (MICS) as a screen for anti-invasive agents. Int J Cancer 43: 449-457
34. Westerlund A, Hujanen E, Hoyhtya M, Puistola U, Turpeenniemi-Hujanen T (1997) Ovarian cancer cell invasion is inhibited by paclitaxel. Clin Exp Metast 15: 318-328
35. Zondag GC, Evers EE, ten Klooster JP, Janssen L, van der Kammen RA, Collard JG (2000) Oncogenic Ras downregulates Rac activity, which leads to increased Rho activity and epithelial-mesenchymal transition. J Cell Biol 149: 775-782